Acquired DNA mutations in adults with myeloproliferative disorders receiving hydroxyurea therapy.

被引：0
|
作者：
Hanft, VN
Fruchtman, S
Heumayer, S
Weinberg, JB
Howard, TA
Ware, RE
机构：
[1] DUKE UNIV,MED CTR,DURHAM,NC
[2] DURHAM VA HOSP,DURHAM,NC
[3] MT SINAI HOSP,NEW YORK,NY 10029
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1542 / 1542
页数：1
相关论文
共 41 条
  • [31] Impact of DNA damage repair (DDR) mutations on treatment outcomes in men receiving conventional therapy for metastatic castration resistant prostate cancer (mCRPC)
    Carlson, Alex S.
    Acevedo, Rigo
    Lim, Daniel M.
    Gulati, Roman
    Yu, Evan Y.
    Schweizer, Michael Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [32] Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey
    Musengimana, Gentille
    Tuyishime, Elysee
    Kiromera, Athanase
    Malamba, Samuel S.
    Mulindabigwi, Augustin
    Habimana, Madjid R.
    Baribwira, Cyprien
    Ribakare, Muhayimpundu
    Habimana, Savio D.
    DeVos, Josh
    Mwesigwa, Richard C. N.
    Kayirangwa, Eugenie
    Semuhore, Jules M.
    Rwibasira, Gallican N.
    Suthar, Amitabh B.
    Remera, Eric
    ANTIVIRAL THERAPY, 2022, 27 (03)
  • [33] High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy
    Laura Lupini
    Anna Moretti
    Cristian Bassi
    Alessio Schirone
    Massimo Pedriali
    Patrizia Querzoli
    Roberta Roncarati
    Antonio Frassoldati
    Massimo Negrini
    Scientific Reports, 8
  • [34] High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy
    Lupini, Laura
    Moretti, Anna
    Bassi, Cristian
    Schirone, Alessio
    Pedriali, Massimo
    Querzoli, Patrizia
    Roncarati, Roberta
    Frassoldati, Antonio
    Negrini, Massimo
    SCIENTIFIC REPORTS, 2018, 8
  • [35] Management of acute myeloid leukemia (AML) in first relapse: Retrospective analysis about 101 adults cases receiving homogeneous first-line therapy. Impact of prognostic factors and treatment.
    Fohrer, C
    Witz, B
    Harousseau, JL
    Witz, F
    Ame, S
    Maloisel, F
    Bilger, K
    Herbrecht, R
    Lioure, B
    BLOOD, 2004, 104 (11) : 252A - 252A
  • [36] Microsatellite Instability (MSI) In High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Cells Promotes Frameshift Mutations In DNA Repair Genes: Indications for PARP Inhibitor Therapy.
    Gaymes, Terry J.
    Mohamedali, Azim
    Kulasekararaj, Austin G.
    Shall, Sydney
    Mufti, Ghulam J.
    BLOOD, 2010, 116 (21) : 513 - 513
  • [37] Cells bearing FLT3/ITD mutations exhibit elevated repair errors generated through alternative DNA double strand break repair pathways: implications for genomic instability and therapy.
    Fan, Jinshui
    Li, Li
    Small, Donald
    Rassool, Feyruz
    CANCER RESEARCH, 2009, 69
  • [38] MPL W515L/K mutations in 343 Chinese adults with JAK2V617F mutation-negative chronic myeloproliferative disorders detected by a newly developed RQ-PCR based on Taq Man MGB probes
    Ruan, Guo-Rui
    Jiang, Bin
    Li, Ling-Di
    Niu, Ji-Hong
    Li, Jin-Lan
    Xie, Min
    Qin, Ya-Zhen
    Liu, Yan-Rong
    Huang, Xiao-Jun
    Chen, Shan-Shan
    HEMATOLOGICAL ONCOLOGY, 2010, 28 (01) : 33 - 39
  • [39] MSK-ACCESS for the detection of fibroblast growth factor receptor-3 (FGFR3) mutations in plasma cell-free (cf)DNA of metastatic urothelial carcinoma (mUC) patients (pts) pre- and on erdafitinib (erda) therapy.
    Sarfaty, Michal
    Teo, Min Yuen
    Funt, Samuel Aaron
    Lee, Chung-Han
    Aggen, David Henry
    Ratna, Neha
    Regazzi, Ashley Marie
    Al-Ahmadie, Hikmat
    Brannon, Angela Rose
    Berger, Michael F.
    Solit, David B.
    Rosenberg, Jonathan E.
    Bajorin, Dean F.
    Iyer, Gopa
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Single-Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium Protocol 111 Global Phase II Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 12 - 14
12345